Characterization of bradykinin-induced phosphoinositide turnover in neurohybrid NCB-20 cells.
Phosphoinositide hydrolysis was studied in neurohybrid NCB-20 cells prelabeled with myo-[3H]inositol. Among nearly 20 neurotransmitters and neuromodulators examined, only bradykinin, carbachol, and histamine significantly increased the accumulation of [3H]inositol monophosphate (IP1) in the presence of lithium. The EC50 of bradykinin was 20 nM and the saturating concentration was approximately 1 microM. The bradykinin response was robust (10-fold) and was potently and selectively blocked by a bradykinin antagonist, B 4881 [D-Arg-(Hyp3, Thi, D-Phe)-bradykinin], with a Ki of 10 nM. This effect of bradykinin appeared to be additive to that mediated by activation of muscarinic cholinergic and histamine H1 receptors. The accumulation induced by bradykinin or carbachol was dependent on the presence of calcium in the incubation medium; less than twofold stimulation was observed in the absence of exogenous calcium. Bradykinin-induced [3H]IP1 accumulation required high concentration of lithium to elicit its maximal stimulation; the concentration of lithium required for half maximal effect was about 13 mM, similar to the value reported previously for carbachol-induced accumulation in the same cell line. In contrast, using related neurohybrid NG108-15 cells, bradykinin-induced [3H]IP1 accumulation was found to require much less lithium. IN the presence of lithium, bradykinin also evoked a transient increase in the production of [3H]-inositol bis- and trisphosphate. Basal and bradykinin-induced phosphoinositide breakdown was inhibited by 4 beta-phorbol 12,13-dibutyrate, but was unaffected by the biologically inactive 4 beta-phorbol. Pretreatment of cells with pertussis toxin induced only about 30% loss of the bradykinin-induced [3H]IP1 accumulation, without affecting basal activity.(ABSTRACT TRUNCATED AT 250 WORDS)
Chuang
D M
DM
Laboratory of Preclinical Pharmacology, National Institute of Mental Health, St. Elizabeths Hospital, Washington, DC 20032.
Dillon-Carter
O
O
D000818:Animals; D001920:Bradykinin / Q000494:pharmacology*; D002460:Cell Line; D004155:Diphenhydramine / Q000494:pharmacology; D019204:GTP-Binding Proteins / Q000378:metabolism; D007700:Kinetics; D008094:Lithium / Q000494:pharmacology; D015240:Phorbol 12,13-Dibutyrate; D010703:Phorbol Esters / Q000494:pharmacology; D010704:Phorbols / Q000494:pharmacology; D010716:Phosphatidylinositols / Q000378:metabolism*; D014311:Triprolidine / Q000494:pharmacology; D010738:Type C Phospholipases / Q000378:metabolism
D010703:Phorbol Esters; D010704:Phorbols; D010716:Phosphatidylinositols; D014311:Triprolidine; D015240:Phorbol 12,13-Dibutyrate; D004155:Diphenhydramine; D008094:Lithium; D010738:Type C Phospholipases; D019204:GTP-Binding Proteins; D001920:Bradykinin; C033085:phorbol